• John Russell, executive editor of Bio-IT World, profiles Crescendo Bioscience's use of biomarkers in the rise of personalized medicine.
  
  
• Studies Show Vectra™ DA Multi-Biomarker Test Algorithm More Accurate Than Other Established Disease Activity Measures In Identifying Rheumatoid Arthritis Patients At Risk For Joint Damage Progression
  
  
• Crescendo Bioscience Secures $56 Million in Funding to Expand Development and Commercialization of Personalized Diagnostics for Inflammatory Diseases (pdf)
  
  
• Studies Show Crescendo Bioscience's Vectra™ DA Can Track Early Response to Rheumatoid Arthritis Therapy and Predict Joint Damage at the Molecular Level (pdf)
  
  
• Updates from the European League Against Rheumatism (EULAR) Congress 2011 Rheumatology-congress.co.uk website highlights Vectra DA validation data from the 2010 American College of Rheumatology (ACR) Annual Scientific Meeting.
  
  
• Rheumatology-congress.co.uk website highlights Vectra DA validation data from the 2010 American College of Rheumatology (ACR) Annual Scientific Meeting
  
  
• Crescendo Bioscience™, Inc. announces the U.S. launch of the first multi-biomarker blood test for rheumatoid arthritis disease activity.
  
  
• Consortium Announces Study to Investigate Predictive Biomarkers in Patients with Rheumatoid Arthritis Receiving TNF Inhibitors.
  
  
• Updates from the American College of Rheumatology (ACR) 2010 Annual Scientific Meeting
  
  
• Listen to Dr. Moira Gunn and Dr. David Chernoff discuss rheumatoid arthritis and Vectra™ DA.
  
  
• The Institute for Continuing Healthcare Education: Focus on Personalized Medicine